KLK3 and posterior cortical atrophy: In May 2021, [18F]DCFPyL was approved by the FDA for patients with suspected PCa metastases who are candidates for initial definitive therapy, and for patients with suspected recurrence after curable treatment showing increasing serum PSA levels [94].